SCHEMBL16677448

SCHEMBL16677448

CCC(Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1Cl

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 17/20 0.65
PIK3CG P48736 16/20 0.63
PIK3CB P42338 11/20 0.63
PIK3CA P42336 9/20 0.63
PIK3R1 P27986 5/20 0.63
PIK3R2 O00459 1/20 0.63
ABCB11 O95342 1/20 0.63
HTR1A P08908 1/20 0.63
PTGS1 P23219 1/20 0.63
OPRM1 P35372 1/20 0.63
PRKDC P78527 1/20 0.63
SLC6A3 Q01959 1/20 0.63
PDE4D Q08499 1/20 0.63
PDE3A Q14432 1/20 0.63
PIK3C3 Q8NEB9 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16677343 1.00 PIK3CD (0.65) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16677525 1.00 PIK3CD (0.65) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16677464 0.95 PIK3CD (0.64) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16677320 0.95 PIK3CD (0.64) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16677530 0.95 PIK3CD (0.64) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16678040 0.95 PIK3CD (0.66) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16678060 0.95 PIK3CD (0.66) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16678065 0.95 PIK3CD (0.66) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16677508 0.93 PIK3CD (0.71) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1
SCHEMBL16677751 0.93 PIK3CD (0.71) PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015061204-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2015-04-30 WO disclosed